Amgen's Q1 2022 earnings call highlights strong revenue and EPS growth, driven by several key products like Repatha, Prolia, EVENITY, and LUMAKRAS.  Management reaffirmed guidance, indicating continued confidence in the company's trajectory, despite some anticipated headwinds from foreign exchange.  The call also included discussions about the company's tax dispute with the IRS and its strategy for managing and resolving the litigation.

[1]
